Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Market Overview
The ulcerative colitis market was valued at USD 6,854.47 million in 2018, and is also expected to register a CAGR of 4.86% during the forecast period (2019-2024). Ulcerative colitis (UC) is the most common form of inflammatory bowel disease which affects several people. From a global perspective, several research studies in 2018 have reported annual incidence rates of UC ranging from 0.5 to 24.5 cases per 100,000 people. On the other hand, incidences have been increasing in Asian and South European countries. In the United States, UC affects an estimated 500,000 people and is the cause of 250,000 doctor visits and 30,000 hospitalizations, each year. UC has an uneven presence in major geographical regions across the world. It is common in most of Europe and North America and uncommon in most of the developing Asian countries. UC is more prevalent among males and has a regional north-to-south variation. One potential explanation is the differences in exposure to ultraviolet light, resulting in relative vitamin D deficiency in countries close to the Arctic. People who live in lower latitudes are more likely to develop UC than those in higher latitudes.
According to the Centers for Disease Control and Prevention (CDC), in 2015, 1.3% of US adults (3 million) reported that they were diagnosed with IBD (either Crohn’s disease or UC). This was a large increase in number from 1999 (0.9% or 2 million adults). According to an article published in PubMed, the highest reported prevalence values were in Europe (UC - 505 per 100,000 people in Norway, Crohn's disease - 322 per 100,000 people in Germany) and North America (UC - 286 per 100,000 people in the United States, Crohn's disease - 319 per 100,000 people in Canada). The high prevalence of the disease is driving the market.
Scope of the Report
As per the scope of the report, ulcerative colitis is a chronic, inflammatory bowel disease that causes inflammation in the digestive tract. Treatment for ulcerative colitis includes medication and surgery. However, the scope of this report includes only medications for the ulcerative colitis disease.
Key Market Trends
Ulcerative Proctitis Segment is Expected to Experience the Fastest Growth during the Forecast Period
Ulcerative proctitis is one of the types of ulcerative colitis. It is considered as the initial manifestation of ulcerative colitis, in which fine ulcerations in the inner linings of mucosa of the large intestine are seen. A survey was conducted by NIH in 2016, to understand the prevalence of disease, which gave results, such as 25% of the pediatric patients surveyed had the disease, and 17 to 21% of the adult patients had ulcerative proctitis. As per this data obtained by the survey, NIH stated that there was a rise in the number of patients suffering from ulcerative proctitis, compared to the previous years. Hence, this segment, by disease type, is believed to experience growth in the future.
North America Region Holds the Largest Market Share of the Ulcerative Colitis Market Currently and is Believed to Follow the Same Trend over the Forecast Period
North America is expected to lead the ulcerative colitis market, owing to the presence of key players and increasing prevalence of the disease in the region, along with the continuing funding for the development of new therapeutics for the treatment of the condition.
Competitive Landscape
The ulcerative colitis market consists of several major players, including AbbVie Inc., Merck Co., Johnson and Johnson, and many others. The companies are implement certain strategic initiatives, such as merger, new product launch, acquisition, and partnerships that help them in strengthening their market position. For instance, in May 2018, Takeda Pharmaceutical Company Limited and Shire PLC announced that they reached an agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support
The ulcerative colitis market was valued at USD 6,854.47 million in 2018, and is also expected to register a CAGR of 4.86% during the forecast period (2019-2024). Ulcerative colitis (UC) is the most common form of inflammatory bowel disease which affects several people. From a global perspective, several research studies in 2018 have reported annual incidence rates of UC ranging from 0.5 to 24.5 cases per 100,000 people. On the other hand, incidences have been increasing in Asian and South European countries. In the United States, UC affects an estimated 500,000 people and is the cause of 250,000 doctor visits and 30,000 hospitalizations, each year. UC has an uneven presence in major geographical regions across the world. It is common in most of Europe and North America and uncommon in most of the developing Asian countries. UC is more prevalent among males and has a regional north-to-south variation. One potential explanation is the differences in exposure to ultraviolet light, resulting in relative vitamin D deficiency in countries close to the Arctic. People who live in lower latitudes are more likely to develop UC than those in higher latitudes.
According to the Centers for Disease Control and Prevention (CDC), in 2015, 1.3% of US adults (3 million) reported that they were diagnosed with IBD (either Crohn’s disease or UC). This was a large increase in number from 1999 (0.9% or 2 million adults). According to an article published in PubMed, the highest reported prevalence values were in Europe (UC - 505 per 100,000 people in Norway, Crohn's disease - 322 per 100,000 people in Germany) and North America (UC - 286 per 100,000 people in the United States, Crohn's disease - 319 per 100,000 people in Canada). The high prevalence of the disease is driving the market.
Scope of the Report
As per the scope of the report, ulcerative colitis is a chronic, inflammatory bowel disease that causes inflammation in the digestive tract. Treatment for ulcerative colitis includes medication and surgery. However, the scope of this report includes only medications for the ulcerative colitis disease.
Key Market Trends
Ulcerative Proctitis Segment is Expected to Experience the Fastest Growth during the Forecast Period
Ulcerative proctitis is one of the types of ulcerative colitis. It is considered as the initial manifestation of ulcerative colitis, in which fine ulcerations in the inner linings of mucosa of the large intestine are seen. A survey was conducted by NIH in 2016, to understand the prevalence of disease, which gave results, such as 25% of the pediatric patients surveyed had the disease, and 17 to 21% of the adult patients had ulcerative proctitis. As per this data obtained by the survey, NIH stated that there was a rise in the number of patients suffering from ulcerative proctitis, compared to the previous years. Hence, this segment, by disease type, is believed to experience growth in the future.
North America Region Holds the Largest Market Share of the Ulcerative Colitis Market Currently and is Believed to Follow the Same Trend over the Forecast Period
North America is expected to lead the ulcerative colitis market, owing to the presence of key players and increasing prevalence of the disease in the region, along with the continuing funding for the development of new therapeutics for the treatment of the condition.
Competitive Landscape
The ulcerative colitis market consists of several major players, including AbbVie Inc., Merck Co., Johnson and Johnson, and many others. The companies are implement certain strategic initiatives, such as merger, new product launch, acquisition, and partnerships that help them in strengthening their market position. For instance, in May 2018, Takeda Pharmaceutical Company Limited and Shire PLC announced that they reached an agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
